NASDAQ:INCY - Incyte Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $81.75 +1.25 (+1.55 %) (As of 05/26/2019 07:05 AM ET)Previous Close$81.75Today's Range$80.26 - $82.3152-Week Range$57.00 - $88.83Volume1.46 million shsAverage Volume1.44 million shsMarket Capitalization$17.53 billionP/E Ratio99.70Dividend YieldN/ABeta1.31 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware. Receive INCY News and Ratings via Email Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INCY Previous Symbol CUSIP45337C10 CIK879169 Webhttp://www.incyte.com/ Phone302-498-6700Debt Debt-to-Equity Ratio0.01 Current Ratio5.22 Quick Ratio5.21Price-To-Earnings Trailing P/E Ratio99.70 Forward P/E Ratio45.93 P/E GrowthN/A Sales & Book Value Annual Sales$1.88 billion Price / Sales9.32 Cash Flow$1.1323 per share Price / Cash Flow72.20 Book Value$9.73 per share Price / Book8.40Profitability EPS (Most Recent Fiscal Year)$0.82 Net Income$109.49 million Net Margins12.66% Return on Equity13.28% Return on Assets9.72%Miscellaneous Employees1,367 Outstanding Shares214,439,000Market Cap$17.53 billion Next Earnings Date7/30/2019 (Estimated) OptionableOptionable Incyte (NASDAQ:INCY) Frequently Asked Questions What is Incyte's stock symbol? Incyte trades on the NASDAQ under the ticker symbol "INCY." How were Incyte's earnings last quarter? Incyte Co. (NASDAQ:INCY) posted its earnings results on Tuesday, April, 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Zacks' consensus estimate of $0.33 by $0.29. The biopharmaceutical company earned $497.86 million during the quarter, compared to analysts' expectations of $488 million. Incyte had a net margin of 12.66% and a return on equity of 13.28%. Incyte's revenue for the quarter was up 30.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.01) earnings per share. View Incyte's Earnings History. When is Incyte's next earnings date? Incyte is scheduled to release their next quarterly earnings announcement on Tuesday, July 30th 2019. View Earnings Estimates for Incyte. What price target have analysts set for INCY? 21 brokerages have issued 1 year price objectives for Incyte's stock. Their forecasts range from $74.00 to $140.11. On average, they anticipate Incyte's stock price to reach $91.5694 in the next year. This suggests a possible upside of 12.0% from the stock's current price. View Analyst Price Targets for Incyte. What is the consensus analysts' recommendation for Incyte? 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Incyte. What are Wall Street analysts saying about Incyte stock? Here are some recent quotes from research analysts about Incyte stock: 1. According to Zacks Investment Research, "Incyte’s lead drug, Jakafi continues to maintain momentum for the company, as the underlying patient demand for the drug remains strong for both MF and PV. Incyte is working to expand the drug’s label into additional indications which should further boost sales. The FDA approval of Olumiant 2 mg, for which the company received a milestone payment from Lilly, is a positive. Shares have outperformed the industry in the past six months. However, pipeline setbacks continue to be a concern. The FDA’s extension of the review period of the sNDA for the label expansion of Jakafi to treat acute GVHD was disappointing. Earlier, Incyte suffered a setback with the failure of the phase III ECHO-301 study, evaluating epacadostat in combination with Keytruda." (4/29/2019) 2. Raymond James analysts commented, "We are reiterating our Strong Buy rating for Incyte. This morning, the company announced that the FDA has accepted for priority review its supplemental new drug application (sNDA) for Jakafi for the treatment of patients with steroid-refractory acute graft versus host disease (SR-aGVHD). The priority review grants a 6 month review period by the FDA, resulting in a PDUFA date of approximately March 25, 2019. Based on positive data from the REACH1 study, we remain confident regarding Incyte’s expansion into the steroid refractory GVHD market, which we estimate to be a ~$500 million market opportunity in the U.S." (10/25/2018) 3. Cantor Fitzgerald analysts commented, ". We are increasing our price target to $74 from $73 and reiterating our Neutral rating on INCY. At the ongoing ESMO, INCY provided updated Fight-202 results in cholangiocarcinoma, which looked superior to the previously disclosed initial data. Additionally, in a late-breaker presentation, Novartis (NVS, Not Covered) reported Phase II results from its MET inhibitor capmatinib in MET-mutated advanced non-small cell lung cancer (NSCLC) patients. Note that NVS received worldwide rights for capmatinib from INCY. NVS reported promising response rate data that compare favorably to earlier reported results from any MET inhibitors." (10/21/2018) Has Incyte been receiving favorable news coverage? Media coverage about INCY stock has been trending positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Incyte earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of Incyte's key competitors? Some companies that are related to Incyte include Iqvia (IQV), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Sorrento Therapeutics (SRNE), Geovax Labs (GOVX), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY) and Pieris Pharmaceuticals (PIRS). What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Array Biopharma (ARRY), Celgene (CELG) and Freeport-McMoRan (FCX). Who are Incyte's key executives? Incyte's management team includes the folowing people: Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 59)Ms. Maria E. Pasquale, Exec. VP & Gen. CounselDr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 56)Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 52)Ms. Christiana Stamoulis, Exec. VP & CFO (Age 48) Who are Incyte's major shareholders? Incyte's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.21%), Geode Capital Management LLC (1.17%), Northern Trust Corp (0.94%), Pictet Asset Management Ltd. (0.84%), OppenheimerFunds Inc. (0.81%) and Manning & Napier Group LLC (0.75%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, David W Gryska, Eric H Siegel, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein, Vijay K Iyengar and Yao Wenqing. View Institutional Ownership Trends for Incyte. Which major investors are selling Incyte stock? INCY stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Scout Investments Inc., Pictet Asset Management Ltd., Rhenman & Partners Asset Management AB, Banco Santander S.A., Morgan Stanley, Broadfin Capital LLC and Schonfeld Strategic Advisors LLC. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Paul Trower, Paula J Swain, Vijay K Iyengar and Yao Wenqing. View Insider Buying and Selling for Incyte. Which major investors are buying Incyte stock? INCY stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Eagle Asset Management Inc., Victory Capital Management Inc., Argent Capital Management LLC, Frontier Capital Management Co. LLC, JPMorgan Chase & Co. and AQR Capital Management LLC. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte. How do I buy shares of Incyte? Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Incyte's stock price today? One share of INCY stock can currently be purchased for approximately $81.75. How big of a company is Incyte? Incyte has a market capitalization of $17.53 billion and generates $1.88 billion in revenue each year. The biopharmaceutical company earns $109.49 million in net income (profit) each year or $0.82 on an earnings per share basis. Incyte employs 1,367 workers across the globe. What is Incyte's official website? The official website for Incyte is http://www.incyte.com/. How can I contact Incyte? Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected] MarketBeat Community Rating for Incyte (NASDAQ INCY)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 1,008 (Vote Outperform)Underperform Votes: 508 (Vote Underperform)Total Votes: 1,516MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: Why is Cost of Capital Important? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.